Neurogene (NASDAQ:NGNE – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a note issued to investors on Wednesday, Benzinga reports. They presently have a $65.00 price objective on the stock. HC Wainwright‘s price target points to a potential upside of 133.56% from the company’s previous close.
A number of other research analysts also recently weighed in on NGNE. Guggenheim upped their price target on Neurogene from $69.00 to $81.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Canaccord Genuity Group dropped their price target on Neurogene from $180.00 to $166.00 and set a “buy” rating on the stock in a research note on Wednesday, August 12th. William Blair raised Neurogene to a “strong-buy” rating in a research note on Wednesday, September 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neurogene in a research note on Thursday, October 15th. Finally, Wall Street Zen downgraded Neurogene from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 10th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $80.29.
View Our Latest Analysis on Neurogene
Neurogene Stock Up 3.1%
Neurogene (NASDAQ:NGNE – Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($1.53) EPS for the quarter, missing analysts’ consensus estimates of ($1.42) by ($0.11). As a group, equities analysts predict that Neurogene will post -5.88 earnings per share for the current year.
Institutional Investors Weigh In On Neurogene
Several institutional investors and hedge funds have recently bought and sold shares of NGNE. BlackRock Inc. bought a new position in shares of Neurogene in the 2nd quarter worth approximately $33,274,000. Trails Edge Capital Partners LP bought a new position in shares of Neurogene in the 2nd quarter worth approximately $22,483,133. Moore Capital Management LP bought a new position in shares of Neurogene in the 2nd quarter worth approximately $4,454,000. Deutsche Bank AG bought a new position in shares of Neurogene in the 2nd quarter worth approximately $3,354,000. Finally, Wellington Management Group LLP bought a new position in shares of Neurogene in the 2nd quarter worth approximately $987,000. Hedge funds and other institutional investors own 52.37% of the company’s stock.
About Neurogene
Neurogene Inc (NASDAQ: NGNE) is a clinical-stage biotechnology company focused on developing genetic medicines for patients with rare neurological diseases. The company designs gene therapies intended to address the underlying genetic causes of disorders for which treatment options are limited or unavailable.
Neurogene’s lead program is NGN-401, an investigational gene therapy being developed for Rett syndrome, a rare neurodevelopmental disorder. The company is also advancing NGN-101 for CLN5 Batten disease, a form of neuronal ceroid lipofuscinosis.
See Also
- Five stocks we like better than Neurogene
- Sherwin-Williams Remains Evergreen in a Frozen Housing Market
- Palantir’s Q3 Bar Is Higher Than It Looks: 3 Numbers to Watch
- Johnson Controls Beats the Heat in AI Data Centers
- 3 Growth Stocks Under $20 With Hard Catalyst Dates Ahead
Receive News & Ratings for Neurogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurogene and related companies with MarketBeat.com's FREE daily email newsletter.
